Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 429738, 9 pages
http://dx.doi.org/10.1155/2013/429738
Research Article

Chinese Medicine Formula Lingguizhugan Decoction Improves Beta-Oxidation and Metabolism of Fatty Acid in High-Fat-Diet-Induced Rat Model of Fatty Liver Disease

1Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
2Shanghai East Hospital, Tongji University, Shanghai 200120, China
3Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
4E-Institute of Shanghai Municipal Education Commission, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received 21 March 2013; Accepted 11 April 2013

Academic Editor: Yong Qing Yang

Copyright © 2013 Tao Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Q. Ming-Liang, M. Jing-Yuan, W. Jia-Ying, and W. Xian-Liang, “A Meta-analysis: effect of Linggui Zhugan or added formula on chronic heart failure,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 17, no. 16, pp. 243–247, 2011. View at Google Scholar
  2. G. Xiao-Yin, L. Xiao-Qiu, L. Xi-Qing, W. He-Wei, and T. Yan-Jing, “The effect of modification of Lingguizhugan decoction on serum arrial natriuretic factor and cardiac function of congestive heart failure disease of rabbits,” Journal of Emergency in Traditional Chinese Medicine, vol. 15, no. 3, pp. 289–290, 2006. View at Google Scholar
  3. F. Hai-Yan, H. Jin-Ling, S. Fang-Fang et al., “Effects of Linggui Zhugan Decoction on levels of angiotensin II, endothelin-1, tumor necrosis factor-α and interleukin-1β in rats with chronic heart failure,” Journal of Anhui Traditional Chinese Medical College, vol. 29, no. 2, pp. 53–55, 2010. View at Google Scholar
  4. G. A. Ding, G. H. Yu, S. C. Liang et al., “Jiawei lingguizhugan tang for obesity induced by psychoactive drugs,” Chinese Journal of Clinical Rehabilitation, vol. 10, no. 43, pp. 46–48, 2006. View at Google Scholar · View at Scopus
  5. Z. Qi, J. Yong, and C. Jian-Bin, “The experimental study on the influence of Lingguizhugan Decoction on the hemorheology in hyperlipidemic rats,” Journal of Chengdu Unversity of Tarditional Chinese Medicine, vol. 26, no. 3, pp. 11–14, 2003. View at Google Scholar
  6. D. S. Chen, B. Ke, Y. J. Huang et al., “Effects of the modified linggui zhugan decoction (see text) combined with short-term very low calorie diets on glycemic control in newly diagnosed type 2 diabetics,” Journal of Traditional Chinese Medicine, vol. 31, no. 3, pp. 185–188, 2011. View at Google Scholar
  7. H. F. Wei, T. Liu, L. J. Xing, P. Y. Zheng, and G. Ji, “Distribution pattern of traditional Chinese medicine syndromes in 793 patients with fatty liver disease,” Journal of Chinese Integrative Medicine, vol. 7, no. 5, pp. 411–417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Miao, L. Tao, W. Hua-Feng, X. Lian-Jun, Z. Pei-Yong, and J. Guang, “Clinical study of “Jiangzhi Granule” and behavioral intervention for nonalcoholic fatty liver disease of phlegm and blood-stasis syndrome,” Shanghai Journal of Traditional Chinese Medicine, vol. 44, no. 4, pp. 11–13, 2010. View at Google Scholar
  9. T. Liu, L.-L. Yang, L. Zhang, H.-Y. Song, D.-F. Li, and G. Ji, “Comparative study on the effects of different therapeutic methods in preventing and treating nonalcoholic fatty liver in rats,” Journal of Chinese Integrative Medicine, vol. 10, no. 10, pp. 1120–1126, 2012. View at Google Scholar
  10. K. G. Li, The Handouts of Jingui Yaolüe, Shanghai Scientific and Technical Publishers, 1995.
  11. S. Zong-Hua, F. Dong, X.U. Jun-Bo, and B. Kai-Shun, “Study on the compatibility and therapeutical basis of composite herbal medicines of Lingguishugan Decoction,” Chinese Traditional Patent Medicine, vol. 25, no. 5, pp. 132–137, 2003. View at Google Scholar
  12. C. X. Chen, Pharmacology of Traditional Chinese Medicine, Shanghai Scientific and Technical Publishers, Shanghai, China, 2006.
  13. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Pramfalk, M. Pedrelli, and P. Parini, “Role of thyroid receptor β in lipid metabolism,” Biochimica et Biophysica Acta, vol. 1812, no. 8, pp. 929–937, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Gullberg, M. Rudling, C. satló, D. Forrest, B. Angelin, and B. Vennstrِm, “Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice,” Molecular Endocrinology, vol. 16, no. 8, pp. 1767–1777, 2002. View at Google Scholar
  16. E. E. Cable, P. D. Finn, J. W. Stebbins et al., “Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist,” Hepatology, vol. 49, no. 2, pp. 407–417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. F. Louet, C. Le May, J. P. Pégorier, J. F. Decaux, and J. Girard, “Regulation of liver carnitine palmitoyltransferase I gene expression by hormones and fatty acids,” Biochemical Society Transactions, vol. 29, no. 2, pp. 310–316, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Napal, P. F. Marrero, and D. Haro, “An intronic peroxisome proliferator-activated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A,” Journal of Molecular Biology, vol. 354, no. 4, pp. 751–759, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. H. M. Dann and J. K. Drackley, “Carnitine palmitoyltransferase I in liver of periparturient dairy cows: effects of prepartum intake, postpartum induction of ketosis, and periparturient disorders,” Journal of Dairy Science, vol. 88, no. 11, pp. 3851–3859, 2005. View at Google Scholar · View at Scopus
  20. K. G. Sim, J. Hammond, and B. Wilcken, “Strategies for the diagnosis of mitochondrial fatty acid β-oxidation disorders,” Clinica Chimica Acta, vol. 323, no. 1-2, pp. 37–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. P. M. Barger and D. P. Kelly, “PPAR signaling in the control of cardiac energy metabolism,” Trends in Cardiovascular Medicine, vol. 10, no. 6, pp. 238–245, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Musso, R. Gambino, and M. Cassader, “Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD),” Progress in Lipid Research, vol. 48, no. 1, pp. 1–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Drynan, P. A. Quant, and V. A. Zammit, “Flux control exerted by mitochondrial outer membrane carnitine palmitoyltransferase over β-oxidation, ketogenesis and tricarboxylic acid cycle activity in hepatocytes isolated from rats in different metabolic states,” Biochemical Journal, vol. 317, no. 3, pp. 791–795, 1996. View at Google Scholar · View at Scopus
  24. J. Chen, Z. Q. Xie, S. Ye, K. Wang, S. D. Wang, and Q. H. Zhang, “Effect of Ginkgo biloba extract (GBE50) on the metabolism of triglyceride in HepG2 cells,” Chinese Pharmacological Bulletin, vol. 26, no. 7, pp. 961–964, 2010. View at Google Scholar · View at Scopus
  25. R. L. Dobbins, L. S. Szczepaniak, B. Bentley, V. Esser, J. Myhill, and J. Denis McGarry, “Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats,” Diabetes, vol. 50, no. 1, pp. 123–130, 2001. View at Google Scholar · View at Scopus
  26. M. Stefanovic-Racic, G. Perdomo, B. S. Mantell, I. J. Sipula, N. F. Brown, and R. M. O'Doherty, “A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels,” American Journal of Physiology, Endocrinology and Metabolism, vol. 294, no. 5, pp. E969–E977, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Lee, J. Kerner, and C. L. Hoppel, “Mitochondrial carnitine palmitoyltransferase 1a (CPT1a) is part of an outer membrane fatty acid transfer complex,” Journal of Biological Chemistry, vol. 286, no. 29, pp. 25655–25662, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Hashimoto, M. Yamada, S. Matsumoto, T. Monden, T. Satoh, and M. Mori, “Mouse sterol response element binding protein-1c gene expression is negatively regulated by thyroid hormone,” Endocrinology, vol. 147, no. 9, pp. 4292–4302, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Y. Liu and G. A. Brent, “Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation,” Trends in Endocrinology and Metabolism, vol. 21, no. 3, pp. 166–173, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. D. Horton, N. A. Shah, J. A. Warrington et al., “Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12027–12032, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Shimano, I. Shimomura, R. E. Hammer et al., “Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene,” Journal of Clinical Investigation, vol. 100, no. 8, pp. 2115–2124, 1997. View at Google Scholar · View at Scopus
  32. J. B. Kim, H. M. Wright, M. Wright, and B. M. Spiegelman, “ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 8, pp. 4333–4337, 1998. View at Google Scholar
  33. N. Yahagi, H. Shimano, A. H. Hasty et al., “Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lepob/Lepob mice,” Journal of Biological Chemistry, vol. 277, no. 22, pp. 19353–19357, 2002. View at Publisher · View at Google Scholar · View at Scopus